Keyphrases
Chronic Lymphocytic Leukemia
100%
Ibrutinib
51%
Bruton Tyrosine Kinase Inhibitor
21%
Bruton's Tyrosine Kinase
17%
Acalabrutinib
14%
Venetoclax
13%
Relapsed or Refractory
12%
Chronic Lymphocytic Leukemia Cells
10%
Leukemia Patients
9%
Adverse Events
7%
Pirtobrutinib
7%
B-cell Receptor Signaling
7%
Previously Treated
7%
B-cell Malignancies
6%
Progression-free Survival
6%
Richter Transformation
6%
Rituximab
6%
Targeted Therapy
5%
BTK Inhibitor
5%
Confidence Interval
5%
Chemoimmunotherapy
5%
Leukemia
5%
Overall Survival
5%
Older Patients
5%
Treatment-naïve
5%
Hematological Malignancies
5%
T Cells
5%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
78%
Ibrutinib
46%
Bruton Tyrosine Kinase Inhibitor
18%
Bruton Tyrosine Kinase
16%
Acalabrutinib
12%
Venetoclax
12%
Adverse Event
9%
Lymphocytic Lymphoma
9%
B Cell
8%
B Lymphocyte Receptor
7%
Chronic Lymphocytic Leukemia
7%
Disease
6%
Richter's Transformation
6%
Leukemia Cell
6%
Progression Free Survival
6%
Cancer
6%
Targeted Therapy
5%
Malignant Neoplasm
5%
Clinical Trial
5%
Rituximab
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
79%
Ibrutinib
42%
Bruton Tyrosine Kinase Inhibitor
16%
Bruton Tyrosine Kinase
15%
Acalabrutinib
14%
Venetoclax
13%
Adverse Event
10%
Lymphocytic Lymphoma
9%
Rituximab
8%
Progression Free Survival
7%
B Lymphocyte Receptor
7%
Malignant Neoplasm
7%
Disease
6%
Clinical Trial
5%
Overall Survival
5%